Clinical Trial Update: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma [EARLY_Phase 1]

View source ↗

Summary

This early-phase study tests daratumumab with dose-adjusted EPOCH for plasmablastic lymphoma and diffuse large B-cell lymphoma across stages I–IV; recruitment i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Plasmablastic Lymphoma

Drugs mentioned

• Daratumumab (daratumumab)
• Dose-Adjusted EPOCH regimen

Snippet

Sponsor: AIDS Malignancy Consortium | Conditions: Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma | EARLY_Phase 1 | Status: RECRUITING